Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease.
The purpose of our study was to understand the protective effects of reduced expression of dynamin-related protein (Drp1) against amyloid beta (Aβ) induced mitochondrial and synaptic toxicities in Alzheimer's disease (AD) progression and pathogenesis. Our recent molecular and biochemical studies revealed that impaired mitochondrial dynamics-increased mitochondrial fragmentation and decreased fusion-in neurons from autopsy brains of AD patients and from transgenic AD mice and neurons expressing Aβ, suggesting that Aβ causes mitochondrial fragmentation in AD. Further, our recent co-immunoprecipitation and immunostaining analysis revealed that the mitochondrial fission protein Drp1 interacted with Aβ, and this interaction increased as AD progressed. Based on these findings, we hypothesize that a partial deficiency of Drp1 inhibits Drp1-Aβ interactions and protects Aβ-induced mitochondrial and synaptic toxicities, and maintains mitochondrial dynamics and neuronal function in AD neurons. We crossed Drp1+/- mice with APP transgenic mice (Tg2576 line) and created double mutant (APPXDrp1+/-) mice. Using real-time RT-PCR and immunoblotting analyses, we measured mRNA expressions and protein levels of genes related to the mitochondrial dynamics, mitochondrial biogenesis and synapses from 6-month-old Drp1+/-, APP, APPXDrp1+/- and wild-type (WT) mice. Using biochemical methods, we also studied mitochondrial function and measured soluble Aβ in brain tissues from all lines of mice in our study. Decreased mRNA expressions and protein levels of Drp1 and Fis1 (fission) and CypD (matrix) genes, and increased levels of Mfn1, Mfn2 and Opa1 (fusion), Nrf1, Nrf2, PGC1α, TFAM (biogenesis) and synaptophysin, PSD95, synapsin 1, synaptobrevin 1, neurogranin, GAP43 and synaptopodin (synaptic) were found in 6-month-old APPXDrp1+/- mice relative to APP mice. Mitochondrial functional assays revealed that mitochondrial dysfunction is reduced in APPXDrp1+/- mice relative to APP mice, suggesting that reduced Drp1enhances mitochondrial function in AD neurons. Sandwich ELISA assay revealed that soluble Aβ levels were significantly reduced in APPXDrp1+/- mice relative to APP mice, indicating that reduced Drp1 decreases soluble Aβ production in AD progression. These findings suggest that a partial reduction of Drp1 reduces Aβ production, reduces mitochondrial dysfunction, and maintains mitochondrial dynamics, enhances mitochondrial biogenesis and synaptic activity in APP mice. These findings may have implications for the development of Drp1 based therapeutics for AD patients.
Garrison Institute on Aging, Texas Tech University Health Sciences Center, MS, Lubbock, TX, USA.
Maria
M
Manczak
Garrison Institute on Aging, Texas Tech University Health Sciences Center, MS, Lubbock, TX, USA.
Ramesh
R
Kandimalla
Garrison Institute on Aging, Texas Tech University Health Sciences Center, MS, Lubbock, TX, USA.
David
D
Fry
Cell Biology Department, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hiromi
H
Sesaki
Garrison Institute on Aging, Texas Tech University Health Sciences Center, MS, Lubbock, TX, USA.|Cell Biology & Biochemistry Department.|Pharmacology & Neuroscience Department.|Neurology Department.|Speech, Language and Hearing Sciences Departments, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
P Hemachandra
PH
Reddy
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000235:genetics* / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D034281:Dynamins / Q000037:antagonists & inhibitors / Q000235:genetics*; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D008928:Mitochondria / Q000235:genetics* / Q000473:pathology; D063154:Mitochondrial Dynamics / Q000187:drug effects; D058990:Molecular Targeted Therapy; D009474:Neurons / Q000378:metabolism / Q000473:pathology; D013569:Synapses / Q000187:drug effects / Q000473:pathology
D016229:Amyloid beta-Peptides; C486391:Dnm1l protein, mouse; D034281:Dynamins
Biochim Biophys Acta. 2016 Apr;1862(4):814-828
26708942
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13145-50
18757748
N Engl J Med. 2010 Jan 28;362(4):329-44
20107219
Nat Med. 2011 Mar;17(3):377-82
21336284
J Cell Biol. 2009 Sep 21;186(6):805-16
19752021
EMBO Mol Med. 2010 Dec;2(12):490-503
21069748
Brain Res Rev. 2011 Jun 24;67(1-2):103-18
21145355
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11830-5
12189211
Hum Mol Genet. 2012 Jan 15;21(2):406-20
21997870
Science. 1996 Oct 4;274(5284):99-102
8810256
Hum Mol Genet. 2015 Dec 20;24(25):7308-25
26464486
Curr Alzheimer Res. 2011 Mar;8(2):187-96
21222606
Trends Mol Med. 2001 Dec;7(12):548-54
11733217
Front Cell Neurosci. 2016 Feb 09;10:24
26903809
Hum Mol Genet. 2014 Mar 15;23(6):1413-24
24154542
Neurology. 1990 Aug;40(8):1302-3
2166249
J Biol Chem. 2006 Sep 29;281(39):29096-104
16849325
J Neurochem. 2004 Jun;89(5):1308-12
15147524
Hum Mol Genet. 2011 Dec 1;20(23):4515-29
21873260
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18670-5
20937894
Neurobiol Aging. 2000 May-Jun;21(3):455-62
10858595
Adv Pharmacol. 2012;64:83-126
22840745
EMBO J. 2006 Aug 23;25(16):3900-11
16874299
Neuromolecular Med. 2004;5(2):147-62
15075441
Hum Mol Genet. 2004 Jun 15;13(12):1225-40
15115763
Med Hypotheses. 2004;63(1):8-20
15193340
Hum Mol Genet. 2010 Oct 15;19(20):3919-35
20660112
Mol Brain. 2010 Nov 13;3:35
21073741
FASEB J. 2005 Dec;19(14):2040-1
16210396
Neurodegener Dis. 2008;5(3-4):157-9
18322377
EMBO J. 2010 Oct 20;29(20):3571-89
20842103
Neurobiol Aging. 2009 Apr;30(4):574-90
17904698
Hum Mol Genet. 2006 May 1;15(9):1437-49
16551656
Nature. 1996 Jul 11;382(6587):120-1
8700201
J Neurosci. 2009 Jul 15;29(28):9090-103
19605646
Science. 2004 Apr 16;304(5669):448-52
15087549
JAMA. 2015 May 19;313(19):1924-38
25988462
Biochim Biophys Acta. 2010 Jan;1802(1):2-10
19853658
J Neurosci. 2006 Aug 30;26(35):9057-68
16943564
J Neurosci. 2005 Jan 19;25(3):672-9
15659604
J Alzheimers Dis. 2016;51(2):571-80
26890765
Hum Mol Genet. 2011 Jul 1;20(13):2495-509
21459773
Hum Mol Genet. 2011 Apr 1;20(7):1438-55
21257639
Hum Mol Genet. 2015 Sep 15;24(18):5198-210
26123488
Physiol Rev. 2001 Apr;81(2):741-66
11274343
Curr Opin Cell Biol. 2011 Aug;23(4):427-34
21565481
Exp Neurol. 2009 Aug;218(2):286-92
19358844
J Neuropathol Exp Neurol. 1994 Sep;53(5):508-12
8083692
Hum Mol Genet. 2012 Jun 1;21(11):2538-47
22367970
J Alzheimers Dis. 2010;20 Suppl 2:S499-512
20413847
Nature. 2004 Aug 5;430(7000):631-9
15295589
J Neurosci. 2013 Oct 23;33(43):17042-51
24155308
J Neural Transm (Vienna). 1998;105(8-9):855-70
9869323
Nat Med. 2008 Oct;14(10):1097-105
18806802
J Neurosci. 2012 Jan 4;32(1):229-42
22219285
Brain Res Mol Brain Res. 1997 Feb;44(1):99-104
9030703
Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14670-5
19667196
Brain Res Mol Brain Res. 1994 Jul;24(1-4):336-40
7968373
Cell. 2011 Nov 11;147(4):893-906
22078885
Biochim Biophys Acta. 2012 May;1822(5):639-49
22037588
Neurobiol Dis. 2013 Mar;51:72-81
22819776
Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19318-23
19050078
Hum Mol Genet. 2009 Oct 15;18(R2):R169-76
19808793
J Alzheimers Dis. 2010;20 Suppl 2:S609-31
20463406
Hum Mol Genet. 2012 May 1;21(9):1931-44
22228096